These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 22350134)
21. Maturity onset diabetes of the young and fibrin-related thrombosis risk. Sagar RC; Phoenix F; Thanabalasingham G; Naseem K; Ajjan RA; Owen KR Diab Vasc Dis Res; 2020; 17(6):1479164120963048. PubMed ID: 33334146 [TBL] [Abstract][Full Text] [Related]
22. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Ekholm E; Shaat N; Holst JJ Acta Diabetol; 2012 Oct; 49(5):349-54. PubMed ID: 21761282 [TBL] [Abstract][Full Text] [Related]
23. Clinical and laboratory clues of maturity-onset diabetes of the young and determination of association with molecular diagnosis. Karaoglan M; Nacarkahya G J Diabetes; 2021 Feb; 13(2):154-163. PubMed ID: 32710514 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992 [TBL] [Abstract][Full Text] [Related]
25. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Stanik J; Dusatkova P; Cinek O; Valentinova L; Huckova M; Skopkova M; Dusatkova L; Stanikova D; Pura M; Klimes I; Lebl J; Gasperikova D; Pruhova S Diabetologia; 2014 Mar; 57(3):480-4. PubMed ID: 24323243 [TBL] [Abstract][Full Text] [Related]
26. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Fendler W; Rizzo M; Borowiec M; Malachowska B; Antosik K; Szadkowska A; Banach M; Urbanska-Kosinska M; Szopa M; Malecki M; Mlynarski W Acta Diabetol; 2014 Aug; 51(4):625-32. PubMed ID: 24549415 [TBL] [Abstract][Full Text] [Related]
27. Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes. Huang X; Gong S; Ma Y; Cai X; Zhou L; Luo Y; Li M; Liu W; Zhang S; Zhang X; Ren Q; Zhu Y; Zhou X; Zhang R; Chen L; Gao X; Zhang F; Wang Y; Han X; Ji L J Diabetes Res; 2018; 2018():7842064. PubMed ID: 30155490 [TBL] [Abstract][Full Text] [Related]
28. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations. Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271 [TBL] [Abstract][Full Text] [Related]
29. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152 [TBL] [Abstract][Full Text] [Related]
30. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young. Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251 [TBL] [Abstract][Full Text] [Related]
32. New clinical screening strategy to distinguish Ma Y; Gong S; Wang X; Cai X; Xiao X; Gu W; Yang J; Zhong L; Xiao J; Li M; Liu W; Zhang S; Zhou X; Li Y; Zhou L; Zhu Y; Luo Y; Ren Q; Huang X; Gao X; Zhang X; Zhang R; Chen L; Wang F; Wang Q; Hu M; Han X; Ji L BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32238361 [TBL] [Abstract][Full Text] [Related]
33. Molecular background and clinical characteristics of HNF1A MODY in a Polish population. Skupien J; Gorczynska-Kosiorz S; Klupa T; Cyganek K; Wanic K; Borowiec M; Sieradzki J; Malecki MT Diabetes Metab; 2008 Nov; 34(5):524-8. PubMed ID: 18838325 [TBL] [Abstract][Full Text] [Related]
34. An alternative approach using hs-CRP levels and age of onset in diagnostics of HNF1A-MODY. Kickova T; Skopkova M; Dobiasova Z; Lackova G; Belicova Z; Schenkova K; Stanik J; Gasperikova D Diabet Med; 2024 May; 41(5):e15265. PubMed ID: 38093550 [TBL] [Abstract][Full Text] [Related]
35. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers. Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960 [TBL] [Abstract][Full Text] [Related]
36. Circulating CD36 is reduced in HNF1A-MODY carriers. Bacon S; Kyithar MP; Schmid J; Costa Pozza A; Handberg A; Byrne MM PLoS One; 2013; 8(9):e74577. PubMed ID: 24069322 [TBL] [Abstract][Full Text] [Related]
37. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA; Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of Retinopathy in Adult Patients with GCK-MODY and HNF1A-MODY. Szopa M; Wolkow J; Matejko B; Skupien J; Klupa T; Wybrańska I; Trznadel-Morawska I; Kiec-Wilk B; Borowiec M; Malecki MT Exp Clin Endocrinol Diabetes; 2015 Oct; 123(9):524-8. PubMed ID: 26240958 [TBL] [Abstract][Full Text] [Related]
40. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young. Wang X; Wang T; Yu M; Zhang H; Ping F; Zhang Q; Xu J; Feng K; Xiao X Acta Diabetol; 2019 Mar; 56(3):281-288. PubMed ID: 30293189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]